Rituximab Biosimilar · Dr. Reddy’s Laboratories
Reditux holds a landmark position in oncology in India. Launched in 2007, it became the world's first biosimilar Rituximab, fundamentally changing access to biologic therapy for patients with Non-Hodgkin's Lymphoma (NHL).
Over the years, Reditux built a deep-rooted association with oncologists — not just as a treatment option, but as a trusted partner in patient care, backed by real-world usage, Indian clinical data, and global regulatory credibility.
In its 18th year, the brand reached a dual milestone: completion of 18 years of clinical usage and trust, and publication of Reditux's first meta-analysis data — a distinction unique to the brand within its category.
After nearly two decades in the market, Reditux was already well-established. The challenge was not awareness, but relevance and renewed belief.
How do you celebrate a mature brand without sounding nostalgic or dated? How do you reinforce trust among doctors who have grown with the brand? How do you elevate a scientific milestone into a compelling brand story?
The core challenge was to reignite belief in Reditux by seamlessly blending its emotional legacy with strong contemporary scientific validation.
“In oncology, belief precedes prescription. Doctors don’t just prescribe molecules — they prescribe based on confidence built over years of experience, evidence, and outcomes.”
I Believe in Evidence, Experience and Efficacy
We began with a core platform reflecting the long-standing trust doctors have placed in Reditux since its launch as the world's first biosimilar Rituximab. This belief was further strengthened by the publication of the brand's first meta-analysis data.
As the brand completed 18 years, we developed creative extensions around the belief associated with the number 18, positioning it as a symbol of completeness, maturity, and excellence:
Through these associations, Reditux's 18-year journey was positioned as one of enduring belief, proven experience, and validated efficacy — seamlessly blending scientific credibility with emotional legacy.











Let's talk about how we can build something meaningful together.
Start a Conversation